Sonoma Pharmaceuticals, Inc. (SNOA)
USD 2.25
(-4.66%)
USD 2.25
(-4.66%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -4.83 Million USD | 6.13% |
| 2023 | -5.15 Million USD | -1.28% |
| 2022 | -5.08 Million USD | -10.21% |
| 2021 | -4.61 Million USD | -56.65% |
| 2020 | -2.94 Million USD | 75.03% |
| 2019 | -11.79 Million USD | 17.66% |
| 2018 | -14.32 Million USD | -254.5% |
| 2017 | 9.27 Million USD | 191.26% |
| 2016 | -10.16 Million USD | -23.88% |
| 2015 | -8.2 Million USD | -319.63% |
| 2014 | 3.73 Million USD | 168.77% |
| 2013 | -5.43 Million USD | 25.9% |
| 2012 | -7.32 Million USD | 7.79% |
| 2011 | -7.94 Million USD | 3.45% |
| 2010 | -8.23 Million USD | 53.38% |
| 2009 | -17.65 Million USD | 13.19% |
| 2008 | -20.33 Million USD | -2.81% |
| 2007 | -19.78 Million USD | 14.36% |
| 2006 | -23.09 Million USD | -39.74% |
| 2005 | -16.53 Million USD | -126.5% |
| 2004 | -7.29 Million USD | -357.55% |
| 2003 | -1.59 Million USD | -855.09% |
| 2002 | -167 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -866 Thousand USD | 41.64% |
| 2024 Q1 | -1.41 Million USD | -8.41% |
| 2024 Q2 | -1.48 Million USD | -4.65% |
| 2024 FY | -4.83 Million USD | 6.13% |
| 2024 Q4 | -1.06 Million USD | -23.21% |
| 2023 Q2 | -1.01 Million USD | -14.66% |
| 2023 Q1 | -887 Thousand USD | 69.87% |
| 2023 Q4 | -1.3 Million USD | 32.54% |
| 2023 FY | -5.15 Million USD | -1.28% |
| 2023 Q3 | -1.93 Million USD | -90.66% |
| 2022 Q2 | -100 Thousand USD | 90.89% |
| 2022 Q4 | -2.94 Million USD | -211.86% |
| 2022 FY | -5.08 Million USD | -10.21% |
| 2022 Q1 | -1.09 Million USD | 70.0% |
| 2022 Q3 | -944 Thousand USD | -844.0% |
| 2021 Q2 | 120 Thousand USD | -87.92% |
| 2021 FY | -4.61 Million USD | -56.65% |
| 2021 Q1 | 993 Thousand USD | 172.27% |
| 2021 Q4 | -3.66 Million USD | -463.08% |
| 2021 Q3 | -650 Thousand USD | -641.67% |
| 2020 Q2 | -1.2 Million USD | -268.25% |
| 2020 FY | -2.94 Million USD | 75.03% |
| 2020 Q3 | -1.08 Million USD | 9.89% |
| 2020 Q4 | -1.37 Million USD | -26.75% |
| 2020 Q1 | 715 Thousand USD | 122.19% |
| 2019 Q2 | -2.82 Million USD | 18.45% |
| 2019 Q3 | -2.29 Million USD | 18.51% |
| 2019 Q1 | -3.45 Million USD | 27.4% |
| 2019 Q4 | -3.22 Million USD | -40.21% |
| 2019 FY | -11.79 Million USD | 17.66% |
| 2018 Q3 | -3.18 Million USD | -11.05% |
| 2018 FY | -14.32 Million USD | -254.5% |
| 2018 Q4 | -4.76 Million USD | -49.45% |
| 2018 Q2 | -2.87 Million USD | 18.19% |
| 2018 Q1 | -3.5 Million USD | -44.01% |
| 2017 Q3 | 16.22 Million USD | 932.63% |
| 2017 Q4 | -2.43 Million USD | -115.01% |
| 2017 Q1 | -2.56 Million USD | 11.75% |
| 2017 FY | 9.27 Million USD | 191.26% |
| 2017 Q2 | -1.94 Million USD | 24.1% |
| 2016 Q3 | -3.14 Million USD | -78.62% |
| 2016 FY | -10.16 Million USD | -23.88% |
| 2016 Q2 | -1.76 Million USD | 24.66% |
| 2016 Q1 | -2.34 Million USD | -55.79% |
| 2016 Q4 | -2.91 Million USD | 7.59% |
| 2015 Q4 | -1.5 Million USD | 74.6% |
| 2015 Q3 | -5.91 Million USD | -723.68% |
| 2015 Q2 | -718 Thousand USD | -925.71% |
| 2015 Q1 | -70 Thousand USD | -100.94% |
| 2015 FY | -8.2 Million USD | -319.63% |
| 2014 Q3 | -611 Thousand USD | 56.33% |
| 2014 Q4 | 7.45 Million USD | 1320.46% |
| 2014 FY | 3.73 Million USD | 168.77% |
| 2014 Q2 | -1.39 Million USD | 18.28% |
| 2014 Q1 | -1.71 Million USD | 29.98% |
| 2013 Q2 | -1.51 Million USD | -441.35% |
| 2013 FY | -5.43 Million USD | 25.9% |
| 2013 Q3 | -1.91 Million USD | -25.87% |
| 2013 Q1 | 445 Thousand USD | 125.17% |
| 2013 Q4 | -2.44 Million USD | -27.88% |
| 2012 Q1 | -2.17 Million USD | -28.39% |
| 2012 Q3 | -2.54 Million USD | -203.58% |
| 2012 FY | -7.32 Million USD | 7.79% |
| 2012 Q4 | -1.76 Million USD | 30.59% |
| 2012 Q2 | -839 Thousand USD | 61.43% |
| 2011 Q2 | -1.64 Million USD | 30.57% |
| 2011 Q3 | -2.23 Million USD | -35.23% |
| 2011 Q4 | -1.69 Million USD | 24.04% |
| 2011 FY | -7.94 Million USD | 3.45% |
| 2011 Q1 | -2.37 Million USD | -63.57% |
| 2010 Q3 | -1.34 Million USD | 28.9% |
| 2010 Q2 | -1.89 Million USD | 46.54% |
| 2010 FY | -8.23 Million USD | 53.38% |
| 2010 Q1 | -3.54 Million USD | -59.15% |
| 2010 Q4 | -1.45 Million USD | -7.88% |
| 2009 Q4 | -2.22 Million USD | 32.98% |
| 2009 Q3 | -3.32 Million USD | 51.97% |
| 2009 Q2 | -6.91 Million USD | -32.95% |
| 2009 Q1 | -5.19 Million USD | -16.18% |
| 2009 FY | -17.65 Million USD | 13.19% |
| 2008 FY | -20.33 Million USD | -2.81% |
| 2008 Q2 | -5.54 Million USD | -10.44% |
| 2008 Q1 | -5.01 Million USD | 20.24% |
| 2008 Q3 | -5.3 Million USD | 4.29% |
| 2008 Q4 | -4.47 Million USD | 15.63% |
| 2007 Q3 | -4.82 Million USD | -11.4% |
| 2007 Q1 | -4.33 Million USD | 35.11% |
| 2007 Q4 | -6.29 Million USD | -30.33% |
| 2007 FY | -19.78 Million USD | 14.36% |
| 2007 Q2 | -4.33 Million USD | 0.0% |
| 2006 Q2 | -4.87 Million USD | 0.0% |
| 2006 Q3 | -6.67 Million USD | -37.07% |
| 2006 Q4 | -6.67 Million USD | 0.01% |
| 2006 FY | -23.09 Million USD | -39.74% |
| 2006 Q1 | -4.87 Million USD | -17.91% |
| 2005 Q2 | -4.13 Million USD | 0.0% |
| 2005 Q3 | -4.13 Million USD | 0.0% |
| 2005 FY | -16.53 Million USD | -126.5% |
| 2005 Q1 | -4.13 Million USD | 0.0% |
| 2005 Q4 | -4.13 Million USD | 0.02% |
| 2004 FY | -7.29 Million USD | -357.55% |
| 2003 FY | -1.59 Million USD | -855.09% |
| 2002 FY | -167 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 110.04% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -56.042% |
| Embecta Corp. | 70.4 Million USD | 106.868% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 111.524% |
| PainReform Ltd. | -9.34 Million USD | 48.256% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -7.3% |
| SCYNEXIS, Inc. | 67.04 Million USD | 107.212% |
| Journey Medical Corporation | -3.85 Million USD | -25.487% |
| Safety Shot Inc | -15.08 Million USD | 67.944% |
| Alpha Teknova, Inc. | -36.78 Million USD | 86.854% |
| Bright Green Corporation | -13.12 Million USD | 63.169% |
| Procaps Group, S.A. | 42.54 Million USD | 111.366% |
| Alvotech | -551.73 Million USD | 99.124% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 125.747% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 38.564% |
| Cosmos Health Inc. | -18.54 Million USD | 73.925% |
| Dynavax Technologies Corporation | -6.38 Million USD | 24.323% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 97.689% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 96.538% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -7.3% |
| Theratechnologies Inc. | -23.95 Million USD | 79.818% |
| Harrow Health, Inc. | -24.41 Million USD | 80.193% |
| Biofrontera Inc. | -20.13 Million USD | 75.982% |
| DURECT Corporation | -27.62 Million USD | 82.497% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 467.401% |
| Cronos Group Inc. | -73.96 Million USD | 93.463% |
| OptiNose, Inc. | -35.48 Million USD | 86.374% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 99.518% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 88.542% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 120.217% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 197.776% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 3159.488% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 23.001% |
| Radius Health, Inc. | -25.79 Million USD | 81.253% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 21.549% |
| ProPhase Labs, Inc. | -16.78 Million USD | 71.189% |
| Phibro Animal Health Corporation | 2.41 Million USD | 300.124% |
| Procaps Group S.A. | 42.54 Million USD | 111.366% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 52.958% |
| Viatris Inc. | 54.7 Million USD | 108.839% |
| Rockwell Medical, Inc. | -8.43 Million USD | 42.706% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 69.484% |
| SIGA Technologies, Inc. | 68.06 Million USD | 107.103% |
| Tilray Brands, Inc. | -244.98 Million USD | 98.026% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 140.248% |
| Shineco, Inc. | -22.44 Million USD | 78.462% |
| PetIQ, Inc. | 2.13 Million USD | 326.889% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -12.394% |
| Incannex Healthcare Limited | -18.45 Million USD | 73.807% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 101.936% |
| Alimera Sciences, Inc. | -20.13 Million USD | 75.984% |
| Silver Spike Investment Corp. | 7.34 Million USD | 165.871% |
| Assertio Holdings, Inc. | -331.94 Million USD | 98.543% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 26.662% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 40.771% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 72.987% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 75.894% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 96.983% |
| Hempacco Co., Inc. | -13.12 Million USD | 63.165% |
| Talphera, Inc. | -18.39 Million USD | 73.719% |
| Alvotech | -551.73 Million USD | 99.124% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 113.565% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 101.48% |
| Currenc Group, Inc. | -15.3 Million USD | 68.412% |
| Kamada Ltd. | 8.28 Million USD | 158.366% |
| Indivior PLC | 2 Million USD | 341.75% |
| Evoke Pharma, Inc. | -7.79 Million USD | 37.952% |
| Flora Growth Corp. | -57.03 Million USD | 91.523% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 75.894% |
| Evolus, Inc. | -61.68 Million USD | 92.162% |
| HUTCHMED (China) Limited | 100.78 Million USD | 104.798% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 103.515% |
| Akanda Corp. | -32.27 Million USD | 85.019% |